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Nowadays, the various surfactants find wide application in pharmaceutical 
industry. The nanoparticle preparation process by emulsion techniques 
essentially requires a surfactant, most commonly Pluronic® F-68 [1]. This non-
ionic tenside influences cell physiology and was tested in clinical trial for the 
treatment of sickle cell disease [2] and myocardial infarction [3]. Out of these 
reasons, even residual tenside in nanoparticle preparations might influence the 
cells as well as their interaction with the colloidal carriers. At this, Caco-2 single 
cells were incubated with fluorescent polystyrene nanoparticles, in presence of 
increasing amounts of Pluronic® F-68 and cell-associated nanoparticles were 
detected by flow cytometry. Independent from incubation temperature, the cell-
associated fraction of nanoparticles concurrently increased with the tenside 
concentration. Ongoing from micropipette aspiration experiments this effect 
could be attributed to an increase of membrane stiffness of Caco-2 cells in 
presence of Pluronic® F-68. Furthermore, the toxicity assay revealed that 
viability of the cells remained unaffected at any concentration of Pluronic® F-68. 
 
All in all, the non-ionic surfactant Pluronic® F-68 not only promises as a 
therapeutic agent but also as a non-toxic enhancer of nanoparticle-cell 
interaction. That way, the challenge (presently existing limit) of reaching 
therapeutic levels in drug therapy with nanoparticles might be overcome. 
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